Aligos Therapeutics (NASDAQ:ALGS) Issues Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) issued its quarterly earnings data on Friday. The company reported ($2.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.28) by $0.19, FiscalAI reports. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $4.85 million.

Aligos Therapeutics Price Performance

NASDAQ ALGS traded down $0.44 during trading hours on Friday, reaching $4.07. 101,665 shares of the company’s stock traded hands, compared to its average volume of 130,776. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69. The firm has a market cap of $25.42 million, a PE ratio of -0.56 and a beta of 2.43. The firm has a 50-day simple moving average of $5.31 and a 200 day simple moving average of $6.17.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group raised shares of Aligos Therapeutics to a “strong-buy” rating in a research note on Friday, September 25th. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. Finally, Weiss Ratings lowered shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Aligos Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.